JP2008543785A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008543785A5 JP2008543785A5 JP2008516024A JP2008516024A JP2008543785A5 JP 2008543785 A5 JP2008543785 A5 JP 2008543785A5 JP 2008516024 A JP2008516024 A JP 2008516024A JP 2008516024 A JP2008516024 A JP 2008516024A JP 2008543785 A5 JP2008543785 A5 JP 2008543785A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- aliphatic
- pain
- ring
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 claims 27
- 125000001931 aliphatic group Chemical group 0.000 claims 22
- 125000005843 halogen group Chemical group 0.000 claims 18
- 125000001424 substituent group Chemical group 0.000 claims 15
- -1 1,2-methylenedioxy Chemical group 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 12
- 229920006395 saturated elastomer Polymers 0.000 claims 12
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 229910052717 sulfur Inorganic materials 0.000 claims 10
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- 208000002193 Pain Diseases 0.000 claims 8
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 6
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 6
- 125000002723 alicyclic group Chemical group 0.000 claims 6
- 125000001118 alkylidene group Chemical group 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 4
- 208000004296 neuralgia Diseases 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 4
- 208000008035 Back Pain Diseases 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 208000005298 acute pain Diseases 0.000 claims 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 2
- 206010003591 Ataxia Diseases 0.000 claims 2
- 208000000003 Breakthrough pain Diseases 0.000 claims 2
- 206010058019 Cancer Pain Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- 208000004404 Intractable Pain Diseases 0.000 claims 2
- 206010028836 Neck pain Diseases 0.000 claims 2
- 208000004550 Postoperative Pain Diseases 0.000 claims 2
- 208000008765 Sciatica Diseases 0.000 claims 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 208000013403 hyperactivity Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 101100516563 Caenorhabditis elegans nhr-6 gene Proteins 0.000 claims 1
- 208000006561 Cluster Headache Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical class O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 206010061533 Myotonia Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 claims 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000018912 cluster headache syndrome Diseases 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000015706 neuroendocrine disease Diseases 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 125000003003 spiro group Chemical group 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 claims 1
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 claims 1
- 0 ***C(NC(C1)Cc2c1ccc(S(NC1CCCCCC1)(=O)=O)c2)=O Chemical compound ***C(NC(C1)Cc2c1ccc(S(NC1CCCCCC1)(=O)=O)c2)=O 0.000 description 3
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68891905P | 2005-06-09 | 2005-06-09 | |
| PCT/US2006/022818 WO2006133459A1 (en) | 2005-06-09 | 2006-06-09 | Indane derivatives as modulators of ion channels |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012076707A Division JP2012126745A (ja) | 2005-06-09 | 2012-03-29 | イオンチャネルの調節因子としてのインダン誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008543785A JP2008543785A (ja) | 2008-12-04 |
| JP2008543785A5 true JP2008543785A5 (cg-RX-API-DMAC7.html) | 2009-09-24 |
Family
ID=37000013
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008516024A Ceased JP2008543785A (ja) | 2005-06-09 | 2006-06-09 | イオンチャネルの調節因子としてのインダン誘導体 |
| JP2012076707A Withdrawn JP2012126745A (ja) | 2005-06-09 | 2012-03-29 | イオンチャネルの調節因子としてのインダン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012076707A Withdrawn JP2012126745A (ja) | 2005-06-09 | 2012-03-29 | イオンチャネルの調節因子としてのインダン誘導体 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7605174B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1888547A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2008543785A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20080019693A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101238109B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006254809B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2611731A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL187997A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2007015726A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20080141L (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ564374A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2007148504A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006133459A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200800191B (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7615563B2 (en) * | 2003-08-08 | 2009-11-10 | Gonzalez Iii Jesus E | Compositions useful as inhibitors of voltage-gated sodium channels |
| EP1891063B1 (en) * | 2005-05-10 | 2012-07-25 | Vertex Pharmaceuticals, Inc. | Bicyclic derivatives as modulators of ion channels |
| KR20080021030A (ko) * | 2005-05-16 | 2008-03-06 | 버텍스 파마슈티칼스 인코포레이티드 | 이온 채널 조절인자로서의 바이사이클릭 유도체 |
| CA2622076A1 (en) * | 2005-09-09 | 2007-03-15 | Vertex Pharmaceuticals Incorporated | Bicyclic derivatives as modulators of voltage gated ion channels |
| RU2008113209A (ru) | 2005-10-06 | 2009-10-10 | Санофи-Авентис (Fr) | Бициклические {1, 3, 4}тиадиазол-2-иламиды арилсульфоновой кислоты, способы их получения и их использование в качестве фармацевтических средств |
| JP2009512717A (ja) * | 2005-10-21 | 2009-03-26 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネルを調節するための誘導体 |
| TW200740803A (en) * | 2005-12-21 | 2007-11-01 | Vertex Pharma | Heterocyclic derivatives as modulators of ion channels |
| CA2687764A1 (en) | 2007-05-25 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| US7994174B2 (en) * | 2007-09-19 | 2011-08-09 | Vertex Pharmaceuticals Incorporated | Pyridyl sulfonamides as modulators of ion channels |
| MX2010005307A (es) * | 2007-11-13 | 2010-07-28 | Vertex Pharma | Derivados heterociclicos como moduladores de canales de iones. |
| JP2011503112A (ja) * | 2007-11-13 | 2011-01-27 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の処置のためのイオンチャンネルのモジュレーターとしての４（−３−（−２−（フェニル）モルホリノ）−２−オキソピロリジン−１−イル）−ｎ−（チアゾール−２−イル）ベンゼンスルホンアミド誘導体および関連化合物 |
| US20110031892A1 (en) * | 2008-04-30 | 2011-02-10 | Sharp Kabushiki Kaisha | Lighting device and display device |
| WO2010002956A2 (en) * | 2008-07-01 | 2010-01-07 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| CA2732757A1 (en) * | 2008-08-06 | 2010-02-11 | Merck Sharp & Dohme Corp. | Substituted dihydroisoquinolinone and isoquinolinedione derivatives as calcium channel blockers |
| JP2014532660A (ja) * | 2011-10-28 | 2014-12-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 電位作動型ナトリウムチャネルにおける選択活性を有するベンゾオキサゾリノン化合物 |
| AU2013332648B2 (en) | 2012-10-15 | 2017-09-07 | In Therapeutics | Sodium channel blockers, preparation method thereof and use thereof |
| AR094667A1 (es) | 2013-01-31 | 2015-08-19 | Vertex Pharma | Piridonamidas como moduladores de canales de sodio |
| MX389003B (es) | 2016-05-19 | 2025-03-20 | Tabula Rasa Healthcare Inc | Métodos de tratamiento que tienen toxicidad relacionada con fármacos reducida y métodos para identificar la probabilidad de daño que surja de medicamentos recetados a pacientes. |
| CA3105657A1 (en) | 2018-07-09 | 2020-01-16 | Lieber Institute, Inc. | Pyridine carboxamide compounds for inhibiting nav1.8 |
| CN112689629B (zh) | 2018-07-09 | 2024-04-23 | 利伯研究所公司 | 用于抑制Nav1.8的哒嗪化合物 |
| US20220162169A1 (en) * | 2019-02-20 | 2022-05-26 | Jiangsu Hengrui Medicine Co., Ltd. | 6-oxo-1,6-dihydropyridazine prodrug derivative, preparation method therefor, and application thereof in medicine |
| EP4334298A1 (en) | 2021-06-14 | 2024-03-13 | Scorpion Therapeutics, Inc. | Urea derivatives which can be used to treat cancer |
| CN116041230B (zh) * | 2023-01-08 | 2024-03-19 | 中国海洋大学 | 一种nlrp3炎症小体抑制剂及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| GB9800750D0 (en) * | 1998-01-14 | 1998-03-11 | Lilly Co Eli | Pharmaceutical compound |
| TWI243164B (en) * | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| CA2539227A1 (en) * | 2003-08-08 | 2005-02-17 | Vertex Pharmaceuticals Incorporated | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
-
2006
- 2006-06-09 MX MX2007015726A patent/MX2007015726A/es active IP Right Grant
- 2006-06-09 KR KR1020087000464A patent/KR20080019693A/ko not_active Withdrawn
- 2006-06-09 RU RU2007148504/04A patent/RU2007148504A/ru not_active Application Discontinuation
- 2006-06-09 CA CA002611731A patent/CA2611731A1/en not_active Abandoned
- 2006-06-09 EP EP06772925A patent/EP1888547A1/en not_active Withdrawn
- 2006-06-09 CN CN2006800287819A patent/CN101238109B/zh not_active Expired - Fee Related
- 2006-06-09 NZ NZ564374A patent/NZ564374A/en not_active IP Right Cessation
- 2006-06-09 WO PCT/US2006/022818 patent/WO2006133459A1/en not_active Ceased
- 2006-06-09 AU AU2006254809A patent/AU2006254809B2/en not_active Ceased
- 2006-06-09 JP JP2008516024A patent/JP2008543785A/ja not_active Ceased
- 2006-06-09 US US11/450,695 patent/US7605174B2/en active Active
- 2006-06-09 ZA ZA200800191A patent/ZA200800191B/xx unknown
-
2007
- 2007-12-09 IL IL187997A patent/IL187997A0/en unknown
-
2008
- 2008-01-09 NO NO20080141A patent/NO20080141L/no not_active Application Discontinuation
-
2009
- 2009-08-31 US US12/550,649 patent/US7989481B2/en active Active
-
2012
- 2012-03-29 JP JP2012076707A patent/JP2012126745A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008543785A5 (cg-RX-API-DMAC7.html) | ||
| JP2009511599A5 (cg-RX-API-DMAC7.html) | ||
| JP2009524591A5 (cg-RX-API-DMAC7.html) | ||
| KR101826371B1 (ko) | 신규 히드록삼산 유도체 | |
| JP2008540661A5 (cg-RX-API-DMAC7.html) | ||
| IL268756A (en) | Piprazine – 2,5 – deion derivatives, pharmaceutical preparations containing them and their use in the preparation of medicines | |
| JP2009507851A5 (cg-RX-API-DMAC7.html) | ||
| JP5468007B2 (ja) | 新規なプロスタグランジンｉ２誘導体 | |
| RU2007148504A (ru) | Индановые производные в качестве модуляторов ионных каналов | |
| KR101510975B1 (ko) | 이상지질혈증의 치료에 적절한 헤테로시클릭 화합물 | |
| TW200521108A (en) | Compounds having lysophosphatidic acid receptor(LPA)-antagonizing effect and their use | |
| JP5144670B2 (ja) | ２−フェニル−６−アミノカルボニル−ピリミジン誘導体及びｐ２ｙ１２受容体拮抗剤としてのそれらの使用 | |
| KR20070091013A (ko) | 아미노카르복실산 유도체 및 그 의약 용도 | |
| JP2008509146A5 (cg-RX-API-DMAC7.html) | ||
| CA2659184A1 (en) | Ep2 agonists | |
| RU2007146769A (ru) | Бициклические производные и их применение в качестве модуляторов ионых каналов | |
| RU2008113836A (ru) | Бициклические производные в качестве модуляторов потенциалозависимых ионных каналов | |
| RU2008118350A (ru) | Бифенильные производные в качестве модуляторов потенциалзависимых ионных каналов | |
| JP7399171B2 (ja) | 腎疾患に対するシュウ酸カルシウム結晶化阻害剤 | |
| US11261154B2 (en) | Benzene derivative | |
| ES2945062T3 (es) | Derivados de ácido barbitúrico novedosos, su preparación y uso de los mismos como inhibidores de la transmigración de leucocitos y para el tratamiento de enfermedades inflamatorias, enfermedades autoinmunitarias y cáncer | |
| WO2009019721A3 (en) | Quercetin derivatives as anti-cancer agents | |
| KR101353879B1 (ko) | 백혈병의 치료 또는 예방제 | |
| CN1046285C (zh) | 作为抗增殖剂的稠合杂环谷氨酸衍生物 | |
| WO2017167183A1 (zh) | 二芳基-β-内酰胺类化合物及其制备方法和在制药中的用途 |